Compositions and methods for peptide expression and purification using a type III secretion system
Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.
1. A recombinant cell line comprising:
one or more genomic mutations in a gene selected from the group consisting of fliY, fliF, flgM, araBAD, fliA, fliC, fliD, prgH-hilA, cheV, tcp, yhjH, aer, mcpC, PmotA, motA-cheZ, flhDC, flgM, flgN, flgKL, trg, ycgR, mcpA, fliB, tsr, ecnR, hin-fljA, mcpB, lrhA, ydiV, flgE, and fljB;
a vector comprising a FlgM nucleic acid sequence operably linked to a nucleic acid sequence encoding a purification tag, a cleavage site, a nucleic acid sequence of interest, and a transcription control element (TCE);
wherein the TCE is heterologous to the FlgM nucleic acid sequence;
wherein the 5′ to 3′ order of the sequences is the FlgM nucleic acid sequence, the nucleic acid sequence encoding a purification tag, the cleavage site, and the nucleic acid sequence of interest; and
wherein the recombinant cell line is a Salmonella enterica or an Escherichia coli cell line.
2. The recombinant cell line of claim 1 , wherein the one or more mutations is in a coding region of the gene.
3. The recombinant cell line of claim 1 , wherein the one or more mutations is in a ribosome binding sequence (RBS) of the gene.
4. The recombinant cell line of claim 1 , wherein the one or more mutations is in a promoter of the gene.
5. A recombinant cell line of claim 1 , wherein the one or more mutations is a mutation in fliA.
6. The recombinant cell line of claim 5 , wherein the one or more fliA mutations is selected from the group consisting of V33E; L199R; H14N; H14D; T138 1 ; E203D; R91C; L207P; and a fliA start codon mutation from GTG to ATG.
7. The recombinant cell line of claim 6 , wherein the one or more fliA mutation is selected from the group consisting of:
(a) a double mutant of R91C and L207P;
(b) a triple mutant of H14D, R91C, and L207P;
(c) a double mutant of fliA start codon change from GTG to ATG and H14N; and
(d) a double mutant of fliA start codon change from GTG to ATG and a mutation in the fliA ribosome binding sequence (RBS) to the canonical sequence (CRBS).
8. The recombinant cell line of claim 1 , wherein the purification tag comprises poly-histidine, glutathione S-transferase (GST), Myc, HA, FLAG, or maltose binding protein (MBP).
9. The recombinant cell line of claim 1 , wherein the FlgM nucleic acid sequence of the vector is wild type FlgM.
10. The recombinant cell line of claim 1 , wherein the cleavage site comprises a Tobacco Etch Virus (TEV) protease cleavage site or an Enterokinase (ETK) cleavage site.
11. The recombinant cell line of claim 1 , wherein the nucleic acid sequence of interest encodes a cysteine-rich peptide.
12. The recombinant cell line of claim 11 , wherein the cysteine-rich peptide comprises a neuroactive toxin.
13. The recombinant cell line of claim 1 , wherein the TCE is a constitutive TCE or a regulatable TCE.
14. The recombinant cell line of claim 13 , wherein the regulatable TCE comprises an inducible promoter.
15. The recombinant cell line claim 14 , wherein the inducible promoter comprises a P araBAD promoter.
16. A method of producing a peptide of interest comprising culturing the recombinant cell line of claim 1 in culture media.
17. The method of claim 16 , wherein the bacterial host cell is cultured in media comprising about 200 mM to about 400 mM NaCl or KCl and wherein more of the peptide of interest is produced as compared to bacterial host cells cultured in media comprising 100 mM NaCl or KCl, respectively.